TY  - THES
A1  - Scheide-Nöth, Jan-Philipp
T1  - Activation of the Interleukin-5 receptor and its inhibition by cyclic peptides
T1  - Aktivierung des IL-5 Rezeptors und dessen Inhibierung durch zyklische Peptide
N2  - The cytokine interleukin-5 (IL-5) is part of the TH2-mediated immune response. As a key regulator of eosinophilic granulocytes (eosinophils), IL-5 controls multiple aspects of eosinophil life. Eosinophils play a pathogenic role in the onset and progression of atopic diseases as well as hypereosinophilic syndrome (HES). Here, cytotoxic proteins and pro-inflammatory mediators stored in intracellular vesicles termed granula are released upon activation thereby causing local inflammation to fight the pathogen. However, if such inflammation persists, tissue damage and organ failure can occur. Due to the close relationship between eosinophils and IL-5 this cytokine has become a major pharmaceutical target for the treatment of atopic diseases or HES. As observed with other cytokines, IL-5 signals by assembling a heterodimeric receptor complex at the cell surface in a stepwise mechanism. In the first step IL-5 binds to its receptor IL-5Rα (CD125). This membrane-located complex then recruits the so-called common beta chain βc (CD131) into a ternary ligand receptor complex, which leads to activation of intracellular signaling cascades. Based on this mechanism various strategies targeting either IL-5 or IL-5Rα have been developed allowing to specifically abrogate IL-5 signaling. In addition to the classical approach of employing neutralizing antibodies against IL 5/IL-5Rα or antagonistic IL-5 variants, two groups comprising small 18 to 30mer peptides have been discovered, that bind to and block IL-5Rα from binding its activating ligand IL-5. Structure-function studies have provided detailed insights into the architecture and interaction of IL-5IL-5Rα and βc. However, structural information for the ternary IL-5 complex as well as IL-5 inhibiting peptides is still lacking.
In this thesis three areas were investigated. Firstly, to obtain insights into the second receptor activation step, i.e. formation of the ternary ligand-receptor complex IL-5•IL-5Rα•βc, a high-yield production for the extracellular domain of βc was established to facilitate structure determination of the ternary ligand receptor assembly by either X-ray crystallography or cryo-electron microscopy.
In a second project structure analysis of the ectodomain of IL-5Rα in its unbound conformation was attempted. Data on IL-5Rα in its ligand-free state would provide important information as to whether the wrench-like shaped ectodomain of IL-5Rα adopts a fixed preformed conformation or whether it is flexible to adapt to its ligand binding partner upon interaction. While crystallization of free IL-5Rα failed, as the crystals obtained did not diffract X rays to high resolution, functional analysis strongly points towards a selection fit binding mechanism for IL-5Rα instead of a rigid and fixed IL-5Rα structure. Hence IL-5 possibly binds to a partially open architecture, which then closes to the known wrench-like architecture. The latter is then stabilized by interactions within the D1-D2 interface resulting in the tight binding of IL-5. 
In a third project X-ray structure analysis of a complex of the IL-5 inhibitory peptide AF17121 bound to the ectodomain of IL-5Rα was performed. This novel structure shows how the small cyclic 18mer peptide tightly binds into the wrench-like cleft formed by domains D1 and D2 of IL-5Rα. Due to the partial overlap of its binding site at IL-5Rα with the epitope for IL-5 binding, the peptide blocks IL-5 from access to key residues for binding explaining how the small peptide can effectively compete with the rather large ligand IL-5. While AF17121 and IL-5 seemingly bind to the same site at IL-5Rα, functional studies however showed that recognition and binding of both ligands differ. With the structure for the peptide-receptor complex at hand, peptide design and engineering could be performed to generate AF17121 analogies with enhanced receptor affinity. Several promising positions in the peptide AF17121 could be identified, which could improve inhibition capacity and might serve as a starting point for AF17121-based peptidomimetics that can yield either superior peptide based IL-5 antagonists or small-molecule-based pharmacophores for future therapies of atopic diseases or the hypereosinophilic syndrome.
N2  - Das Zytokin Interleukin-5 (IL-5) nimmt eine zentrale Rolle im Zellzyklus von eosinophlien Granulozyten (Eosinophile) ein, indem es beispielsweise die Differenzierung, Aktivierung und Apoptose dieser Zellen steuert. Als Immunantwort auf Pathogene kommt es zur Aktivierung von Eosinophilen. Dieses führt zur Freisetzung von in intrazellulären Vesikeln (Granula) gespeicherten zytotoxischen Proteinen und proinflammatorischen Mediatoren, wodurch lokale Entzündungen verursacht werden, um den Erreger zu bekämpfen. Fehlregulationen (übermäßige Produktion) von eosinophilen Granulozyten können zu Gewebeschäden und Organversagen führen, wenn diese über einen längeren Zeitraum bestehen, und sind insbesondere mit dem Ausbruch und Fortschreiten von atopischen Erkrankungen sowie dem Hypereosinophilen Syndrom (HES) assoziiert. IL-5 muss, um die Eosinophilen aktivieren zu können, an einen heterodimeren Transmembranrezeptor binden. Im ersten Schritt bindet IL-5 an seinen zytokin-spezifischen Rezeptor IL-5Rα (CD125). Dieser membrangebundene Komplex rekrutiert dann die sogenannte gemeinsame („common“) beta-Kette βc (CD131) in einen ternären Liganden Rezeptorkomplex, was zur Aktivierung von intrazellulären Signalkaskaden führt. Aufgrund dieser engen Beziehung zwischen Eosinophilen und IL-5 ist dieses Zytokin in den Fokus der pharmazeutischen Industrie für die Behandlung atopischer Erkrankungen oder HES gerückt. Bisherige Therapien basieren auf der Unterdrückung der Immunreaktion durch Corticosteroide, neutralisierende gegen IL 5/IL-5Rα gerichtete Antikörper oder antagonistische IL-5 Varianten. Eine alternative Therapiemöglichkeit stellen IL-5 inhibierende Peptide dar, welche an IL 5Rα binden und hierbei die Bindung des aktivierenden Liganden (IL-5) hemmen. Derzeit stehen Strukturen vom binären IL-5IL-5Rα Komplex und von βc im ungebundenen Zustand zur Verfügung. Zudem konnten wichtige Wechselwirkungen im binären Komplex identifiziert werden. Allerdings sind vom ternären IL-5 Komplex und den IL-5 inhibierenden Peptiden keinerlei Strukturdaten bekannt.
Um im Rahmen dieser Arbeit Einblicke in den zweiten Rezeptoraktivierungsschritt, d.h. die Bildung des ternären Ligand-Rezeptor Komplexes IL-5•IL-5Rα•βc, zu erhalten, wurde ein Herstellungsverfahren für die extrazelluläre Domäne von βc etabliert. Zusammen mit den optimierten Reinigungsverfahren für IL-5 und IL 5Rα konnte hiermit eine gute Grundlage für zukünftige Strukturanalysen des ternären IL-5 Komplexes geschaffen werden. In einem zweiten Projekt wurde versucht, die Struktur der Ektodomäne von IL 5Rα in ihrem freien Zustand aufzuklären. Diese Strukturdaten würden wichtige Informationen darüber liefern, ob die bisher bekannte „Schraubenschlüssel“-Architektur der IL-5Rα Ektodomäne in einer rigiden, vorgebildeten Konformation vorliegt, oder ob die Architektur der Ektodomäne bei Bindung flexibel an ihren Liganden angepasst wird. Während die Kristallisation von IL-5Rα ohne einen Bindepartner fehlschlug, deuten neue Funktionsanalysen auf einen „selection fit binding mechanism“ für IL-5Rα hin. Der relativ große Ligand IL-5 bindet daher sehr wahrscheinlich an eine teilweise „offene“ Rezeptorkonformation, die erst nach Bindung die bekannte „Schraubenschlüssel“-Architektur annimmt. In einem dritten Projekt wurde eine Strukturanalyse des Komplexes des IL-5 inhibierenden AF17121 Peptids gebunden an die Ektodomäne von IL-5Rα durchgeführt. Anhand dieser neuen Struktur lässt sich erklären, wie das kleine zyklische 18mer Peptid effektiv mit dem wesentlich größeren Liganden IL-5 um die Bindung am Rezeptor konkurrieren kann. Aufgrund der Überlappung der Bindestellen von AF17121 und IL-5 am Rezeptor IL 5Rα blockiert das Peptid den Zugang von IL-5 an seinen Rezeptor. Obwohl AF17121 und IL-5 in einem ähnlich Strukturbereich in IL-5Rα binden, zeigen funktionelle Studien, dass sich Erkennung und Bindung beider Liganden unterscheiden. Mit der vorliegenden Struktur vom Peptid Rezeptor Komplex konnte ein strukturbasiertes Peptid-Design durchgeführt und so AF17121 Varianten mit verbesserter Rezeptorbindung erzeugt werden. Dabei wurden mehrere Positionen im Peptid AF17121 identifiziert, die dessen Inhibierungseigenschaften möglicherweise verbessern. Somit konnte ein weiterer Grundstein für die Entwicklung von effektiveren Peptid-basierten IL 5 Antagonisten oder sogar nicht-peptidischen Inhibitoren für zukünftige Therapieansätze gegen atopische Erkrankungen oder HES gelegt werden.
KW  - Interleukin 5
KW  - Eosinophiler Granulozyt
KW  - atopic diseases
KW  - eosinophil
KW  - interleukin-5 signaling
KW  - peptide-based interleukin-5 inhibitor
KW  - peptide engineering
KW  - receptor
KW  - functional studies
KW  - structure analysis
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-182504
ER  - 
TY  - JOUR
A1  - Milanos, Sinem
A1  - Elsharif, Shaimaa A.
A1  - Janzen, Dieter
A1  - Buettner, Andrea
A1  - Villmann, Carmen
T1  - Metabolic Products of Linalool and Modulation of GABA\(_{A}\) Receptors
JF  - Frontiers in Chemistry
N2  - Terpenoids are major subcomponents in aroma substances which harbor sedative physiological potential. We have demonstrated that various monoterpenoids such as the acyclic linalool enhance GABAergic currents in an allosteric manner in vitro upon overexpression of inhibitory α1β2 GABA\(_{A}\) receptors in various expression systems. However, in plants or humans, i.e., following intake via inhalation or ingestion, linalool undergoes metabolic modifications including oxygenation and acetylation, which may affect the modulatory efficacy of the generated linalool derivatives. Here, we analyzed the modulatory potential of linalool derivatives at α1β2γ2 GABA\(_{A}\) receptors upon transient overexpression. Following receptor expression control, electrophysiological recordings in a whole cell configuration were used to determine the chloride influx upon co-application of GABA EC\(_{10-30}\) together with the modulatory substance. Our results show that only oxygenated linalool metabolites at carbon 8 positively affect GABAergic currents whereas derivatives hydroxylated or carboxylated at carbon 8 were rather ineffective. Acetylated linalool derivatives resulted in non-significant changes of GABAergic currents. We can conclude that metabolism of linalool reduces its positive allosteric potential at GABAA receptors compared to the significant potentiation effects of the parent molecule linalool itself.
KW  - Cys-loop receptor
KW  - GABA\(_{A}\)
KW  - receptor
KW  - linalool
KW  - linalyl acetate
KW  - oxygenation
KW  - patch-clamp
Y1  - 2017
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-170779
VL  - 5
IS  - 46
ER  - 
TY  - JOUR
A1  - Perkovic, Vlado
A1  - Agarwal, Rajiv
A1  - Fioretto, Paola
A1  - Hemmelgarn, Brenda R.
A1  - Levin, Adeera
A1  - Thomas, Merlin C.
A1  - Wanner, Christoph
A1  - Kasiske, Bertram L.
A1  - Wheeler, David C.
A1  - Groop, Per-Henrik
T1  - Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) controversies conference
JF  - Kidney International
N2  - The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.
KW  - stage renal-disease
KW  - converting enzyme-inhibition
KW  - dietary sodium restriction
KW  - intensive glucose control
KW  - albumin excretion rate
KW  - blood pressure
KW  - cardiovascular outcomes
KW  - randomized trial
KW  - glycemic control
KW  - receptor
KW  - antidiabetic agents
KW  - cardiovascular disease
KW  - chronic kidney disease
KW  - diabetes
KW  - renoprotection
KW  - antagonist
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-186599
VL  - 90
IS  - 6
ER  - 
TY  - JOUR
A1  - Ruck, Tobias
A1  - Bittner, Stefan
A1  - Afzali, Ali Maisam
A1  - Göbel, Kerstin
A1  - Glumm, Sarah
A1  - Kraft, Peter
A1  - Sommer, Claudia
A1  - Kleinschnitz, Christoph
A1  - Preusse, Corinna
A1  - Stenzel, Werner
A1  - Wiendl, Heinz
A1  - Meuth, Sven G.
T1  - The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies
JF  - Oncotarget
N2  - NKG2D is an activating receptor on T cells, which has been implicated in the pathogenesis of autoimmune diseases. T cells are critically involved in idiopathic inflammatory myopathies (IIM) and have been proposed as specific therapeutic targets. However, the mechanisms underlying T cell-mediated progressive muscle destruction in IIM remain to be elucidated. We here determined the involvement of the NKG2D - IL-15 signaling pathway. Primary human myoblasts expressed NKG2D ligands, which were further upregulated upon inflammatory stimuli. In parallel, shedding of the soluble NKG2D ligand MICA (sMICA) decreased upon inflammation potentially diminishing inhibition of NKG2D signaling. Membrane-related expression of IL-15 by myoblasts induced differentiation of naive CD8\(^+\) T cells into highly activated, cytotoxic \(CD8^+NKG2D^{high}\) T cells demonstrating NKG2D-dependent lysis of myoblasts in vitro. \(CD8^+NKG2D^{high}\) T cell frequencies were increased in the peripheral blood of polymyositis (PM) patients and correlated with serum creatinine kinase concentrations, while serum sMICA levels were not significantly changed. In muscle biopsy specimens from PM patients expression of the NKG2D ligand MICA/B was upregulated, IL-15 was expressed by muscle cells, CD68\(^+\) macrophages as well as CD4\(^+\) T cells, and \(CD8^+NKG2D^+\) cells were frequently detected within inflammatory infiltrates arguing for a local signaling circuit in the inflammatory muscle milieu. In conclusion, the NKG2D - IL-15 signaling pathway contributes to progressive muscle destruction in IIM potentially opening new therapeutic avenues.
KW  - MIC ligands
KW  - pathology section
KW  - T cell activation
KW  - idiopathic inflammatory myopathies
KW  - polymyositis
KW  - IL-15
KW  - NKG2D
KW  - receptor
KW  - expression
KW  - lymphokine-activated killer
KW  - human muscle-cells
KW  - multiple sclerosis
KW  - celiac disease
KW  - tumor immunity
KW  - NKG2D ligands
KW  - cutting edge
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-136047
VL  - 6
IS  - 41
ER  - 
TY  - JOUR
A1  - Tilstam, Pathricia V.
A1  - Gijbels, Marion J.
A1  - Habbeddine, Mohamed
A1  - Cudejko, Celine
A1  - Asare, Yaw
A1  - Theelen, Wendy
A1  - Zhou, Baixue
A1  - Döring, Yvonne
A1  - Drechsler, Maik
A1  - Pawig, Lukas
A1  - Simsekyilmaz, Sakine
A1  - Koenen, Rory R.
A1  - de Winther, Menno P. J.
A1  - Lawrence, Toby
A1  - Bernhagen, Jürgen
A1  - Zernecke, Alma
A1  - Weber, Christian
A1  - Noels, Heidi
T1  - Bone Marrow-Specific Knock-In of a Non-Activatable Ikkα Kinase Mutant Influences Haematopoiesis but Not Atherosclerosis in Apoe-Deficient Mice
JF  - PLOS ONE
N2  - Background: The Ikkα kinase, a subunit of the NF-kappa B-activating IKK complex, has emerged as an important regulator of inflammatory gene expression. However, the role of Ikkα-mediated phosphorylation in haematopoiesis and atherogenesis remains unexplored. In this study, we investigated the effect of a bone marrow (BM)-specific activation-resistant Ikk alpha mutant knock-in on haematopoiesis and atherosclerosis in mice. 
Methods and Results: Apolipoprotein E (Apoe)-deficient mice were transplanted with BM carrying an activation-resistant Ikkα gene (Ikkα(AA/AA) Apoe(-/-)) or with Ikkα(+/+) Apoe(-/-) BM as control and were fed a high-cholesterol diet for 8 or 13 weeks. Interestingly, haematopoietic profiling by flow cytometry revealed a significant decrease in B-cells, regulatory T-cells and effector memory T-cells in Ikkα(AA/AA) Apoe(-/-) BM-chimeras, whereas the naive T-cell population was increased. Surprisingly, no differences were observed in the size, stage or cellular composition of atherosclerotic lesions in the aorta and aortic root of Ikkα(AA/AA) Apoe(-/-) vs Ikkα(+/+) Apoe(-/-) BM-transplanted mice, as shown by histological and immunofluorescent stainings. Necrotic core sizes, apoptosis, and intracellular lipid deposits in aortic root lesions were unaltered. In vitro, BM-derived macrophages from Ikkα(AA/AA) Apoe(-/-) vs Ikkα(+/+) Apoe(-/-) mice did not show significant differences in the uptake of oxidized low-density lipoproteins (oxLDL), and, with the exception of Il-12, the secretion of inflammatory proteins in conditions of Tnf-α or oxLDL stimulation was not significantly altered. Furthermore, serum levels of inflammatory proteins as measured with a cytokine bead array were comparable. 
Conclusion: Our data reveal an important and previously unrecognized role of haematopoietic Ikkα kinase activation in the homeostasis of B-cells and regulatory T-cells. However, transplantation of Ikkα AA mutant BM did not affect atherosclerosis in Apoe(-/-) mice. This suggests that the diverse functions of Ikkα in haematopoietic cells may counterbalance each other or may not be strong enough to influence atherogenesis, and reveals that targeting haematopoietic Ikkα kinase activity alone does not represent a therapeutic approach.
KW  - NF-KAPPA-B
KW  - regulatory T cells
KW  - indoleamine 2,3-dioxygenase
KW  - dendritic cells
KW  - gene expression
KW  - increases atherosclersosis
KW  - receptor
KW  - inhibition
KW  - pathway
KW  - beta
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117450
VL  - 9
IS  - 2
ER  - 
TY  - JOUR
A1  - van Dinther, Maarten
A1  - Zhang, Juan
A1  - Weidauer, Stella E.
A1  - Boschert, Verena
A1  - Muth, Eva-Maria
A1  - Knappik, Achim
A1  - de Gorter, David J. J.
A1  - van Kasteren, Puck B.
A1  - Frisch, Christian
A1  - Müller, Thomas D.
A1  - ten Dijke, Peter
T1  - Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
JF  - PLoS ONE
N2  - Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of osteoporosis. The exact molecular mechanism by which Sclerostin exerts its antagonistic effects on Wnt signaling in bone forming osteoblasts remains unclear. Here we show that Wnt3a-induced transcriptional responses and induction of alkaline phosphatase activity, an early marker of osteoblast differentiation, require the Wnt co-receptors LRP5 and LRP6. Unlike Dickkopf1 (DKK1), Sclerostin does not inhibit Wnt-3a-induced phosphorylation of LRP5 at serine 1503 or LRP6 at serine 1490. Affinity labeling of cell surface proteins with \([^{125} I]\) Sclerostin identified LRP6 as the main specific Sclerostin receptor in multiple mesenchymal cell lines. When cells were challenged with Sclerostin fused to recombinant green fluorescent protein (GFP) this was internalized, likely via a Clathrin-dependent process, and subsequently degraded in a temperature and proteasome-dependent manner. Ectopic expression of LRP6 greatly enhanced binding and cellular uptake of Sclerostin-GFP, which was reduced by the addition of an excess of non-GFP-fused Sclerostin. Finally, an anti-Sclerostin antibody inhibited the internalization of Sclerostin-GFP and binding of Sclerostin to LRP6. Moreover, this antibody attenuated the antagonistic activity of Sclerostin on canonical Wnt-induced responses.
KW  - gene
KW  - rat model
KW  - Dickkopf proteins
KW  - postmenopausal osteoporosis
KW  - increases bone-formation
KW  - WNT
KW  - LRP6
KW  - density
KW  - receptor
KW  - ligand
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130981
VL  - 8
IS  - 4
ER  - 
TY  - JOUR
A1  - El-Keredy, Amira
A1  - Schleyer, Michael
A1  - König, Christian
A1  - Ekim, Aslihan
A1  - Gerber, Bertram
T1  - Behavioural Analyses of Quinine Processing in Choice, Feeding and Learning of Larval Drosophila
JF  - PLoS One
N2  - Gustatory stimuli can support both immediate reflexive behaviour, such as choice and feeding, and can drive internal reinforcement in associative learning. For larval Drosophila, we here provide a first systematic behavioural analysis of these functions with respect to quinine as a study case of a substance which humans report as "tasting bitter". We describe the dose-effect functions for these different kinds of behaviour and find that a half-maximal effect of quinine to suppress feeding needs substantially higher quinine concentrations (2.0 mM) than is the case for internal reinforcement (0.6 mM). Interestingly, in previous studies (Niewalda et al. 2008, Schipanski et al 2008) we had found the reverse for sodium chloride and fructose/sucrose, such that dose-effect functions for those tastants were shifted towards lower concentrations for feeding as compared to reinforcement, arguing that the differences in dose-effect function between these behaviours do not reflect artefacts of the types of assay used. The current results regarding quinine thus provide a starting point to investigate how the gustatory system is organized on the cellular and/or molecular level to result in different behavioural tuning curves towards a bitter tastant.
KW  - honeybees
KW  - chemosensory system
KW  - bitter taste
KW  - melanogaster
KW  - receptor
KW  - reward
KW  - brain
KW  - organization
KW  - architecture
KW  - perception
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130811
VL  - 7
IS  - 7
ER  - 
TY  - JOUR
A1  - Pils, Stefan
A1  - Kopp, Kathrin
A1  - Peterson, Lisa
A1  - Tascon, Julia Delgado
A1  - Nyffenegger-Jann, Naja J.
A1  - Hauck, Christof R.
T1  - The Adaptor Molecule Nck Localizes the WAVE Complex to Promote Actin Polymerization during CEACAM3-Mediated Phagocytosis of Bacteria
JF  - PLoS One
N2  - Background: CEACAM3 is a granulocyte receptor mediating the opsonin-independent recognition and phagocytosis of human-restricted CEACAM-binding bacteria. CEACAM3 function depends on an intracellular immunoreceptor tyrosine-based activation motif (ITAM)-like sequence that is tyrosine phosphorylated by Src family kinases upon receptor engagement. The phosphorylated ITAM-like sequence triggers GTP-loading of Rac by directly associating with the guanine nucleotide exchange factor (GEF) Vav. Rac stimulation in turn is critical for actin cytoskeleton rearrangements that generate lamellipodial protrusions and lead to bacterial uptake. 
Principal Findings: In our present study we provide biochemical and microscopic evidence that the adaptor proteins Nck1 and Nck2, but not CrkL, Grb2 or SLP-76, bind to tyrosine phosphorylated CEACAM3. The association is phosphorylation-dependent and requires the Nck SH2 domain. Overexpression of the isolated Nck1 SH2 domain, RNAi-mediated knock-down of Nck1, or genetic deletion of Nck1 and Nck2 interfere with CEACAM3-mediated bacterial internalization and with the formation of lamellipodial protrusions. Nck is constitutively associated with WAVE2 and directs the actin nucleation promoting WAVE complex to tyrosine phosphorylated CEACAM3. In turn, dominant-negative WAVE2 as well as shRNA-mediated knock-down of WAVE2 or the WAVE-complex component Nap1 reduce internalization of bacteria. 
Conclusions: Our results provide novel mechanistic insight into CEACAM3-initiated phagocytosis. We suggest that the CEACAM3 ITAM-like sequence is optimized to co-ordinate a minimal set of cellular factors needed to efficiently trigger actin-based lamellipodial protrusions and rapid pathogen engulfment.
KW  - activation
KW  - neisseria gonorrhoeae
KW  - human pathogens
KW  - T cell
KW  - signal transduction
KW  - escherichia coli
KW  - epithelial cells
KW  - tyrosine kinase
KW  - receptor
KW  - adhesion
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131747
VL  - 7
IS  - 3
ER  - 
TY  - JOUR
A1  - Gresle, Melissa M.
A1  - Alexandrou, Estella
A1  - Wu, Qizhu
A1  - Egan, Gary
A1  - Jokubaitis, Vilija
A1  - Ayers, Margaret
A1  - Jonas, Anna
A1  - Doherty, William
A1  - Friedhuber, Anna
A1  - Shaw, Gerry
A1  - Sendtner, Michael
A1  - Emery, Ben
A1  - Kilpatrick, Trevor
A1  - Butzkueven, Helmut
T1  - Leukemia Inhibitory Factor Protects Axons in Experimental Autoimmune Encephalomyelitis via an Oligodendrocyte-Independent Mechanism
JF  - PLoS One
N2  - Leukemia inhibitory factor (LIF) and Ciliary Neurotrophic factor (CNTF) are members of the interleukin-6 family of cytokines, defined by use of the gp130 molecule as an obligate receptor. In the murine experimental autoimmune encephalomyelitis (EAE) model, antagonism of LIF and genetic deletion of CNTF worsen disease. The potential mechanism of action of these cytokines in EAE is complex, as gp130 is expressed by all neural cells, and could involve immuno-modulation, reduction of oligodendrocyte injury, neuronal protection, or a combination of these actions. In this study we aim to investigate whether the beneficial effects of CNTF/LIF signalling in EAE are associated with axonal protection; and whether this requires signalling through oligodendrocytes. We induced MOG\(_{35-55}\) EAE in CNTF, LIF and double knockout mice. On a CNTF null background, LIF knockout was associated with increased EAE severity (EAE grade 2.1\(\pm\)0.14 vs 2.6\(\pm\)0.19; P<0.05). These mice also showed increased axonal damage relative to LIF heterozygous mice, as indicated by decreased optic nerve parallel diffusivity on MRI (1540\(\pm\)207 \(\mu\)m\(^2\)-/s vs 1310\(\pm\)175 \(\mu\)m\(^2\)-/s; P<0.05), and optic nerve (-12.5%) and spinal cord (-16%) axon densities; and increased serum neurofilament-H levels (2.5 fold increase). No differences in inflammatory cell numbers or peripheral auto-immune T-cell priming were evident. Oligodendrocyte-targeted gp130 knockout mice showed that disruption of CNTF/LIF signalling in these cells has no effect on acute EAE severity. These studies demonstrate that endogenous CNTF and LIF act centrally to protect axons from acute inflammatory destruction via an oligodendrocyte-independent mechanism.
KW  - receptor
KW  - ciliary neurotrophic factor
KW  - mulitple-sclerosis patients
KW  - factor prevents
KW  - demyelination
KW  - survival
KW  - neurons
KW  - injury
KW  - degeneration
KW  - motoneurons
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-134617
VL  - 7
IS  - 10
ER  - 
TY  - JOUR
A1  - Buga, Ana-Maria
A1  - Scholz, Claus Jürgen
A1  - Kumar, Senthil
A1  - Herndon, James G.
A1  - Alexandru, Dragos
A1  - Cojocaru, Gabriel Radu
A1  - Dandekar, Thomas
A1  - Popa-Wagner, Aurel
T1  - Identification of New Therapeutic Targets by Genome-Wide Analysis of Gene Expression in the Ipsilateral Cortex of Aged Rats after Stroke
JF  - PLoS One
N2  - Background: Because most human stroke victims are elderly, studies of experimental stroke in the aged rather than the young rat model may be optimal for identifying clinically relevant cellular responses, as well for pinpointing beneficial interventions. 
Methodology/Principal Findings: We employed the Affymetrix platform to analyze the whole-gene transcriptome following temporary ligation of the middle cerebral artery in aged and young rats. The correspondence, heat map, and dendrogram analyses independently suggest a differential, age-group-specific behaviour of major gene clusters after stroke. Overall, the pattern of gene expression strongly suggests that the response of the aged rat brain is qualitatively rather than quantitatively different from the young, i.e. the total number of regulated genes is comparable in the two age groups, but the aged rats had great difficulty in mounting a timely response to stroke. Our study indicates that four genes related to neuropathic syndrome, stress, anxiety disorders and depression (Acvr1c, Cort, Htr2b and Pnoc) may have impaired response to stroke in aged rats. New therapeutic options in aged rats may also include Calcrl, Cyp11b1, Prcp, Cebpa, Cfd, Gpnmb, Fcgr2b, Fcgr3a, Tnfrsf26, Adam 17 and Mmp14. An unexpected target is the enzyme 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 in aged rats, a key enzyme in the cholesterol synthesis pathway. Post-stroke axonal growth was compromised in both age groups. 
Conclusion/Significance: We suggest that a multi-stage, multimodal treatment in aged animals may be more likely to produce positive results. Such a therapeutic approach should be focused on tissue restoration but should also address other aspects of patient post-stroke therapy such as neuropathic syndrome, stress, anxiety disorders, depression, neurotransmission and blood pressure.
KW  - gamma
KW  - corticotropin-releasing hormone
KW  - colony-stimulating factor
KW  - cerebral ischemia
KW  - receptor
KW  - brain
KW  - protein
KW  - inhibitor
KW  - mouse
KW  - differentiation
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130657
VL  - 7
IS  - 12
ER  -